Current topic: Ornithine carbamoyltransferase deficiency

Abstract excerpt

The death of Jesse Gelsinger on 17 September 1999 had major effects on the gene therapy community. It brought to a halt a gene therapy clinical trial at the Institute of Human Gene Therapy, University of Pennsylvania, USA and brought to a wider audience the potential clinical problems associated with this technology.1 In addition a number of clinicians became aware of Jesse's genetic disorder, ornithine...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amino Acid Enzymes and Metabolism
• Share to Metabolism and Genetic Disorders
• Share to Neonatal Health and Biochemistry